Targeted Genetics Corporation Says FDA Removes Hold on Arthritis Drug Trial

Nov 26 (Reuters) - Targeted Genetics Corp (TGEN.O: Quote, Profile, Research) said the U.S. Food and Drug Administration had removed the hold on the company’s early-stage clinical trial of tgACC94 for inflammatory arthritis.

MORE ON THIS TOPIC